TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21932661

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), once a day for 6 consecutive days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group, no treatment specified
Number of subjects: 42
Study: 18377145

Group type: EXPERIMENTAL
Intervention: Family adaptation to illness
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Children's medication use
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Baseline caregiver psychological functioning
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Illness severity
Number of subjects: 140
Study: 16946666

Group type: EXPERIMENTAL
Intervention: High-enrolling surgeons
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Randomized group
Number of subjects: 276

Group type: COMPARATOR
Intervention: Nonrandomized group
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: High-enrolling institutions
Number of subjects: 276

Group type: COMPARATOR
Intervention: Low-enrolling surgeons
Number of subjects: 276
Study: 12683268

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (preferential indication for clozapine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting depot neuroleptic preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics in acute and long-acting intramuscular forms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive medications
Number of subjects: 0
Study: 10935777

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 32
Study: 8826489

Group type: EXPERIMENTAL
Intervention: Topical aspirin/diethyl ether (ADE) mixture
Number of subjects: 37

Group type: COMPARATOR
Intervention: Topical indomethacin/diethyl ether mixture
Number of subjects: 37

Group type: COMPARATOR
Intervention: Topical diclofenac/diethyl ether mixture
Number of subjects: 37
Study: 1419008

Group type: EXPERIMENTAL
Intervention: Amantadine 1 g orally in divided doses over a period of 25 hours prior to surgery, along with diazepam 5 mg orally 1 hour prior to induction of anesthesia.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diazepam 5 mg orally 1 hour prior to induction of anesthesia (Control group).
Number of subjects: 16
Study: 6544198

Group type: EXPERIMENTAL
Intervention: 200 mg sulindac twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 27
Study: 31793646

Group type: EXPERIMENTAL
Intervention: Nutritional supplements for pregnant and lactating women and children 6-59 months of age
Number of subjects: 0
Study: 28459136

Group type: EXPERIMENTAL
Intervention: 2 mg/kg grapiprant (oral administration)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 mg/kg grapiprant (i.v. administration)
Number of subjects: 6
Study: 25624435

Group type: EXPERIMENTAL
Intervention: 38-hour communication skills training program
Number of subjects: 237

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 237
Study: 24220326

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM with routine vaccines
Number of subjects: 529

Group type: COMPARATOR
Intervention: Routine vaccines alone
Number of subjects: 529
Study: 22300651

Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealant
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer with energy supplied
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Resin-composite sealant
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer without energy supplied
Number of subjects: 407
Study: 21158959

Group type: EXPERIMENTAL
Intervention: Dietary intake assessment through 24-h dietary recalls
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Traditional foods
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Shop-bought foods
Number of subjects: 75
Study: 17129731

Group type: EXPERIMENTAL
Intervention: 3-day immobilization
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2-week immobilization
Number of subjects: 30
Study: 15854196

Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori (HP) serology
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HP breath testing
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oesophagogastroduodenoscopy
Number of subjects: 43
Study: 11956421

Group type: EXPERIMENTAL
Intervention: Stented group (7Fr double pigtail stent for 3 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonstented group
Number of subjects: 60
Study: 9864004

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg once daily
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg once daily
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg twice daily
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 7890057

Group type: EXPERIMENTAL
Intervention: Cyclic sodium etidronate and low-dose norethindrone (2.5 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group I)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low-dose norethindrone (10 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group II)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Untreated controls (Group III)
Number of subjects: 19
Study: 2223345

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine plain solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.25% bupivacaine plain solution
Number of subjects: 0
Study: 382485

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no splenectomy)
Number of subjects: 0
Study: 31043177

Group type: EXPERIMENTAL
Intervention: Systemic fluoroquinolones for up to 31 days
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Rifampicin treatment for up to 31 days
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Fracture fixation device infections
Number of subjects: 269
Study: 28293274

Group type: EXPERIMENTAL
Intervention: SOC-On, RVBC-Off, Blood-ROI, Global-DV, Delay-Off
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SOC-On
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RBC-Off
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delay-On
Number of subjects: 12
Study: 25827166

Group type: EXPERIMENTAL
Intervention: Tadalafil/finasteride
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo/finasteride
Number of subjects: 695
Study: 23488307

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertension without vitamin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (uncomplicated pregnancies)
Number of subjects: 0
Study: 20383544

Group type: EXPERIMENTAL
Intervention: Immediate implant loading within 1 week after implant insertion
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional loading of palatal implants after a healing period of 12 weeks
Number of subjects: 41
Study: 19448380

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (12.5 g carbohydrates/100 ml, pH 5.0) given shortly before surgery
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 17394937

Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 0
Study: 16640169

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting, lipophilic CCBs
Number of subjects: 0
Study: 11934726

Group type: EXPERIMENTAL
Intervention: Prolonged methylprednisolone administration
Number of subjects: 0
Study: 9806049

Group type: COMPARATOR
Intervention: Ganciclovir from engraftment without prior acyclovir treatment (Group 1)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Ganciclovir for CMV pp65 antigenemia without prior acyclovir (Group 2)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Ganciclovir at engraftment with prior intravenous acyclovir (500 mg/m2 every 8 h) (Group 3)
Number of subjects: 359
Study: 7625499

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU at 1 and 3 months, 100,000 IU at 6 and 9 months, 200,000 IU at 12 and 15 months)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 118
Study: 1973844

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Lithium carbonate (Li)
Number of subjects: 105
Study: 347294

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (5.1 x 10(5) U per kilogram per day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (higher dosages)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (two highest dosage levels)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 90
Study: 31424576

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 chemotherapy with SIRT (yttrium-90 resin microspheres)
Number of subjects: 472

Group type: COMPARATOR
Intervention: mFOLFOX6 chemotherapy without SIRT (control arm)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Both arms (SIRT and Control)
Number of subjects: 472
Study: 29336621

Group type: EXPERIMENTAL
Intervention: Beta-Alanine (3.2 g/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Resistance Training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 26818850

Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone (5 mg/kg IV loading dose, continuous infusion of 10-15 μg/kg/min for 3 days)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 25212919

Group type: EXPERIMENTAL
Intervention: Multimodal physical exercise program for 16 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 67
Study: 22174436

Group type: EXPERIMENTAL
Intervention: 1-g dose of doripenem administered intravenously over 4 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-g dose of doripenem administered intravenously over 4 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: 500 mg and 1 g doses of doripenem administered over 4 hours in adult healthy volunteers (HVs)
Number of subjects: 0
Study: 21050302

Group type: EXPERIMENTAL
Intervention: Regular mammography screening
Number of subjects: 0
Study: 17638548

Group type: EXPERIMENTAL
Intervention: IVU before SWL (n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: SWL without IVU (n = 100)
Number of subjects: 200
Study: 16412928

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% instilled hourly for 10 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% instilled hourly for 10 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% instilled 4 times a day for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% instilled 4 times a day for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% and Moxifloxacin 0.5%
Number of subjects: 0
Study: 12441586

Group type: EXPERIMENTAL
Intervention: Chicken Soup for the Soul at Work Employee Groups intervention, consisting of nine weekly meetings.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group, no specific intervention mentioned.
Number of subjects: 0
Study: 10465313

Group type: EXPERIMENTAL
Intervention: Bayesian interim analysis methods for monitoring randomized controlled Phase II trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 7570433

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 5 mg and ipratropium bromide 500 micrograms (4 times a day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nebulised salbutamol 5 mg alone (4 times a day)
Number of subjects: 70
Study: 2405936

Group type: EXPERIMENTAL
Intervention: Aust pyloroplasty (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (pylorus left intact, group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (gastric emptying test)
Number of subjects: 40
Study: 519476

Group type: EXPERIMENTAL
Intervention: Praziquantel 30 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel split regimen (two doses of 20 mg/kg given four hours apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel (all regimens)
Number of subjects: 0
Study: 30594109

Group type: EXPERIMENTAL
Intervention: Weight suppression (difference between highest past and current weight)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Baseline body fat (covariate)
Number of subjects: 294
Study: 27853049

Group type: EXPERIMENTAL
Intervention: Monthly regimen (MR): 1.5 g iv methylprednisolone monthly for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Weekly regimen (WR): 0.5 g iv methylprednisolone weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks
Number of subjects: 40
Study: 25597555

Group type: EXPERIMENTAL
Intervention: Impaired olfaction (defined as an olfactory score below the fifth percentile of normative data)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Impaired olfaction
Number of subjects: 165
Study: 23863351

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min, daily for five days a week, for three weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study: 21807137

Group type: EXPERIMENTAL
Intervention: NSAID (ibuprofen)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19743621

Group type: EXPERIMENTAL
Intervention: modified multidrug therapy (mMDT) including rifampicin, clofazimine, and dapsone for 1 year
Number of subjects: 794

Group type: COMPARATOR
Intervention: Control group (137 patients observed)
Number of subjects: 794
Study: 17082663

Group type: EXPERIMENTAL
Intervention: Thrice-weekly low-dose rituximab (20 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thrice-weekly low-dose rituximab (60 mg/m2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard dose infusion of rituximab (375 mg/m2)
Number of subjects: 12
Study: 15278031

Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP group)
Number of subjects: 171

Group type: COMPARATOR
Intervention: No omentoplasty (NO group)
Number of subjects: 171
Study: 11402249

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO) 1.0 g á kg body mass(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 10
Study: 9424000

Group type: EXPERIMENTAL
Intervention: Sucralfate (3 g in 15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Number of subjects: 86
Study: 8098520

Group type: EXPERIMENTAL
Intervention: Topical 1% apraclonidine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 3030392

Group type: EXPERIMENTAL
Intervention: Combined oestrogen-CPA therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 31982885

Group type: EXPERIMENTAL
Intervention: Levosimendan (treatment group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 30561169

Group type: EXPERIMENTAL
Intervention: Peripheral blood minimal residual disease (PB-MRD) assessment at day 8
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: PB-MRD assessment at days 33 and 52
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Kinetic assessment of PB-MRD
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Day 15 bone marrow MRD (BM-MRD)
Number of subjects: 288
Study: 28961678

Group type: EXPERIMENTAL
Intervention: Linkage-to-care within 365 days of testing HIV-positive
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Younger age (≤30 years) vs >40 years
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Age 31-40 years vs >40 years
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Not being South African
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Urban district
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Being employed
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Nondisclosure of HIV status
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Higher CD4 counts
Number of subjects: 2398
Study: 25542604

Group type: EXPERIMENTAL
Intervention: Active laser treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 2
Study: 23399552

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 8067

Group type: COMPARATOR
Intervention: Nonselective NSAIDs (nsNSAIDs)
Number of subjects: 8067
Study: 21729462

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Vitamin A + Zn supplementation
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Zn supplementation
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Overall growth faltering
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Prenatal supplementation
Number of subjects: 343
Study: 18455961

Group type: EXPERIMENTAL
Intervention: Inhibitory low-frequency rTMS over contralesional motor cortex (20 min, 1200 stimuli) once per day for 8 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhibitory low-frequency rTMS over contralesional motor cortex
Number of subjects: 10
Study: 16522992

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/d
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 8 mg/d (if needed)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Doxazosin GITS and Placebo
Number of subjects: 175
Study: 15264442

Group type: EXPERIMENTAL
Intervention: Participants imagining they had won a lottery and responding to a 34-item questionnaire
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gender of participants
Number of subjects: 80
Study: 11217682

Group type: EXPERIMENTAL
Intervention: Combined vaccine against tetanus, diphtheria and polio (Td-IPV)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Separate Td and IPV injections
Number of subjects: 500
Study: 9387055

Group type: EXPERIMENTAL
Intervention: Antihyperthyroid therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (patients in remission)
Number of subjects: 14
Study: 8329293

Group type: EXPERIMENTAL
Intervention: Moclobemide treatment (200 mg twice daily)
Number of subjects: 70
Study: 3791629

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg every 12 hr for one week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30348097

Group type: EXPERIMENTAL
Intervention: Caregiver training program delivered in non-medical settings for five days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 27460004

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MYmind protocol) consisting of 8 weekly 1.5-hour sessions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Short-acting methylphenidate administered individually
Number of subjects: 120
Study: 24881730

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg once daily)
Number of subjects: 1717
Study: 23342564

Group type: EXPERIMENTAL
Intervention: Oxidative potential water (OPW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% NaOCl (control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of OPW and NaOCl
Number of subjects: 40
Study: 21164394

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 18795522

Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.0 mm (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.4 mm (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.6 mm (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.8 mm (Group D)
Number of subjects: 40
Study: 15920062

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg daily for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 12704548

Group type: EXPERIMENTAL
Intervention: Sclerotherapy performed concurrently with surgical intervention (group A)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Sclerotherapy performed 28 days after surgical intervention (group B)
Number of subjects: 198
Study: 11459384

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nutritional therapy (NT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of cognitive and nutritional therapy (CNT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Support group (SG)
Number of subjects: 100
Study: 9220308

Group type: EXPERIMENTAL
Intervention: Urapidil (60-120 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7970085

Group type: EXPERIMENTAL
Intervention: Bunazosin retard
Number of subjects: 53

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 53
Study: 3600277

Group type: EXPERIMENTAL
Intervention: antithyroid drug methimazole + thyroxine
Number of subjects: 30

Group type: COMPARATOR
Intervention: beta 1‐selective adrenoceptor blocking agent metoprolol
Number of subjects: 30
Study: 28505303

Group type: EXPERIMENTAL
Intervention: Group-based aerobic exercise (AE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Health-education control (HEC)
Number of subjects: 57